Live
- RRR elected Assembly Dy Speaker unopposed
- Cong wants separate Constitution in J&K
- Modi never read Constitution, hence it is blank for him: Rahul
- AP: Global destination
- Tulsi Gabbard on National Intel
- Tribal women from Lagacharla seek KTR’s support
- India vs Malaysia FIFA Friendly Match Poster Unveiled by CM
- Govt awaits Governor's nod to prosecute KTR
- CM exhibits ignorance with his statements on Guv: Kishan
- Amid buzz over arrest, KTR says he is ready to go to jail
Aurobindo gets USFDA nod for conjunctivitis drug
Highlights
City based pharma company, Aurobindo Pharma has received approval from the USFDA for generic Olopatadine Hydrochloride ophthalmic solution used for treatment of seasonal allergic conjunctivitis and is ready to launch the product in the American market.
New Delhi : City based pharma company, Aurobindo Pharma has received approval from the USFDA for generic Olopatadine Hydrochloride ophthalmic solution used for treatment of seasonal allergic conjunctivitis and is ready to launch the product in the American market.
"The company has received final approval from the USFDA to manufacture and market Olopatadine Hydrochloride Ophthalmic Solution USP in the strength of 0.1 per cent," Aurobindo Pharma said in a filing. The product is generic version of Alcon Laboratories Inc's Patanol ophthalmic solution/ drops in the same strength, it added.
"The approved product has an estimated market size of $235 million for the 12 months ending October 2015, according to IMS," Aurobindo Pharma said. The company currently has a total of 225 abbreviated new drug application (ANDA) approvals (197 final approvals including 10 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA, it added.
Next Story
ADVERTISEMENT
